(7S,9R)-7-[(2S,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 蒽环类药物
• 英文名称: (7S,9R)-7-[(2S,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
• 化学式: C₂₇H₂₉NO₁₀
• 分子量: 527.5
• InChiKey: FOBRROYFZIHTLE-AFZREUDQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  38
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  197
• 氢给体数：
  6
• 氢受体数：
  11

文献信息

• Combination therapies for bladder cancer
  申请人：GENEDIA BIOTECH CO. LTD.

  公开号：US10238688B2

  公开（公告）日：2019-03-26

  The disclosure provides drug combinations and methods for treating human bladder cancer. The drug combination may include mitomycin, or an analog thereof, cisplatin or an alternative platinum drug, and epirubicin or an alternative anthracycline drug and does not include gemcitabine.

  本公开提供了治疗人类膀胱癌的药物组合和方法。药物组合可包括丝裂霉素或其类似物、顺铂或替代铂类药物、表柔比星或替代蒽环类药物，但不包括吉西他滨。
• Fucoidan nanogels and methods of their use and manufacture
  申请人：Memorial Sloan Kettering Cancer Center

  公开号：US10478506B2

  公开（公告）日：2019-11-19

  Described herein are polymeric drug-carrying nanogels that are capable of targeting to P-selectin for the treatment of cancer and other diseases and conditions associated with P-selectin. Furthermore, in certain embodiments, the nanogels presented here offer a drug release mechanism based on acidic pH in the microenvironment of a tumor, thereby providing improved treatment targeting capability and allowing use of lower drug doses, thereby reducing toxicity.

  本文描述的聚合物载药纳米凝胶能够靶向 P-选择素，用于治疗癌症和其他与 P-选择素相关的疾病和病症。此外，在某些实施方案中，本文介绍的纳米凝胶提供了一种基于肿瘤微环境中酸性pH值的药物释放机制，从而提高了治疗靶向能力，并允许使用较低的药物剂量，从而降低了毒性。
• Metabolite Biomarkers For Forecasting The Outcome of Preoperative Chemotherapy For Breast Cancer Treatment
  申请人：Purdue Research Foundation

  公开号：US20140162903A1

  公开（公告）日：2014-06-12

  The present disclosure relates to a panel of metabolite species that is useful for forecasting the outcome of preoperative chemotherapy for the treatment of breast cancer, including methods for identifying and using such metabolite species that can be measured in biological samples taken before treatment. In preferred embodiments, a method of forecasting a treatment outcome before subjecting a breast cancer patient to preoperative chemotherapy is disclosed that includes measuring the concentration of at least one metabolite species in a sample of a biofluid taken from the breast cancer patient before preoperative chemotherapy treatment.
• FUCOIDAN NANOGELS AND METHODS OF THEIR USE AND MANUFACTURE
  申请人：MEMORIAL SLOAN KETTERING CANCER CENTER

  公开号：US20150328254A1

  公开（公告）日：2015-11-19

  Described herein are polymeric drug-carrying nanogels that are capable of targeting to P-selectin for the treatment of cancer and other diseases and conditions associated with P-selectin. Furthermore, in certain embodiments, the nanogels presented here offer a drug release mechanism based on acidic pH in the microenvironment of a tumor, thereby providing improved treatment targeting capability and allowing use of lower drug doses, thereby reducing toxicity.
• Treatment of Cancer
  申请人：VIRTTU BIOLOGICS LIMITED

  公开号：US20150374767A1

  公开（公告）日：2015-12-31

  A method of treating cancer is disclosed, the method comprising simultaneous or sequential administration of a virus and a receptor tyrosine kinase (RTK) inhibitor.